BR112021016913A2 - Método para tratar doenças relacionadas a tnfa - Google Patents
Método para tratar doenças relacionadas a tnfaInfo
- Publication number
- BR112021016913A2 BR112021016913A2 BR112021016913A BR112021016913A BR112021016913A2 BR 112021016913 A2 BR112021016913 A2 BR 112021016913A2 BR 112021016913 A BR112021016913 A BR 112021016913A BR 112021016913 A BR112021016913 A BR 112021016913A BR 112021016913 A2 BR112021016913 A2 BR 112021016913A2
- Authority
- BR
- Brazil
- Prior art keywords
- tnfa
- related diseases
- antibody
- treat
- present
- Prior art date
Links
- 101150033527 TNF gene Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
método para tratar doenças relacionadas a tnfa. a presente prevenção se refere a métodos para tratar doenças relacionadas a tnfa administrando-se subcutaneamente um anticorpo que se liga a tnfa (anticorpo anti-tnfa) ou um fragmento de ligação a antígeno do mesmo. o método de tratamento, composição, kit ou uso, de acordo com a presente invenção, fornece uma vantagem de aprimorar a satisfação do paciente, aprimorando-se a conveniência e a qualidade de vida, isto é, reduzindo-se o tempo exigido para administração e diminuição da duração de permanência de pacientes em um hospital em comparação com a injeção intravenosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190023769 | 2019-02-28 | ||
PCT/KR2020/002886 WO2020175954A1 (ko) | 2019-02-28 | 2020-02-28 | TNFα 관련 질환을 치료하는 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021016913A2 true BR112021016913A2 (pt) | 2021-11-03 |
Family
ID=72239651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021016913A BR112021016913A2 (pt) | 2019-02-28 | 2020-02-28 | Método para tratar doenças relacionadas a tnfa |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220153828A1 (pt) |
JP (1) | JP2022521996A (pt) |
KR (1) | KR20200105439A (pt) |
AR (1) | AR118191A1 (pt) |
BR (1) | BR112021016913A2 (pt) |
CA (1) | CA3130921A1 (pt) |
TW (1) | TW202045137A (pt) |
UY (1) | UY38595A (pt) |
WO (1) | WO2020175954A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3479819T2 (ro) | 2016-06-30 | 2024-07-31 | Celltrion Inc | Preparat farmaceutic lichid stabil |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2868614A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
TWI439284B (zh) * | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
CN106039306A (zh) * | 2011-03-30 | 2016-10-26 | 埃博灵克斯股份有限公司 | 使用针对TNFα的单结构域抗体治疗免疫病症的方法 |
KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
-
2020
- 2020-02-26 AR ARP200100519A patent/AR118191A1/es unknown
- 2020-02-27 UY UY0001038595A patent/UY38595A/es unknown
- 2020-02-27 TW TW109106508A patent/TW202045137A/zh unknown
- 2020-02-28 US US17/430,628 patent/US20220153828A1/en active Pending
- 2020-02-28 KR KR1020200024817A patent/KR20200105439A/ko unknown
- 2020-02-28 CA CA3130921A patent/CA3130921A1/en active Pending
- 2020-02-28 JP JP2021550084A patent/JP2022521996A/ja active Pending
- 2020-02-28 BR BR112021016913A patent/BR112021016913A2/pt unknown
- 2020-02-28 WO PCT/KR2020/002886 patent/WO2020175954A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA3130921A1 (en) | 2020-09-03 |
WO2020175954A1 (ko) | 2020-09-03 |
TW202045137A (zh) | 2020-12-16 |
US20220153828A1 (en) | 2022-05-19 |
KR20200105439A (ko) | 2020-09-07 |
AR118191A1 (es) | 2021-09-22 |
UY38595A (es) | 2020-09-30 |
JP2022521996A (ja) | 2022-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
BR112021009856A8 (pt) | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l | |
BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
BR112022008020A2 (pt) | Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1 | |
BR112023022264A2 (pt) | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo | |
BR112022000231A2 (pt) | Novos métodos | |
MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
BR112021016913A2 (pt) | Método para tratar doenças relacionadas a tnfa | |
BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
AU2021339851A8 (en) | Method of treating amyloidosis | |
BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
BR112023025863A2 (pt) | Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2 | |
BR112022018647A2 (pt) | Métodos para dose de iniciação de tratamentos com aripipazol | |
MX2023003723A (es) | Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico. | |
BR112023002085A2 (pt) | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 | |
BR112022018171A2 (pt) | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer | |
EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
BR112022022329A2 (pt) | Proteínas anticancerígenas | |
BR112021024835A2 (pt) | Tratamento para sinuclenopatias |